Viscosupplementation Devices - Medical Devices Pipeline Assessment, 2019

Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 Viscosupplementation Devices Overview

3 Products under Development

• 3.1 Viscosupplementation Devices - Pipeline Products by Stage of Development
• 3.2 Viscosupplementation Devices - Pipeline Products by Segment
• 3.3 Viscosupplementation Devices - Pipeline Products by Territory
• 3.4 Viscosupplementation Devices - Pipeline Products by Regulatory Path
• 3.5 Viscosupplementation Devices - Pipeline Products by Estimated Approval Date
• 3.6 Viscosupplementation Devices - Ongoing Clinical Trials

4 Viscosupplementation Devices - Pipeline Products under Development by Companies

• 4.1 Viscosupplementation Devices Companies - Pipeline Products by Stage of Development
• 4.2 Viscosupplementation Devices - Pipeline Products by Stage of Development

5 Viscosupplementation Devices Companies and Product Overview

• 5.1 Ampio Pharmaceuticals Inc Company Overview
• 5.2 Anika Therapeutics Inc Company Overview
• 5.3 Carticept Medical Inc Company Overview
• 5.4 Chi2Gel Ltd. Company Overview
• 5.5 Cocoon Biotech, Inc. Company Overview
• 5.6 Flex Biomedical Inc Company Overview
• 5.7 Herng Shan Co Ltd Company Overview
• 5.8 Kalvista Pharmaceuticals Inc Company Overview
• 5.9 KiOmed Pharma Company Overview
• 5.10 Lineage Cell Therapeutics Inc Company Overview
• 5.11 Medytox Inc Company Overview
• 5.12 Moebius Medical Ltd Company Overview
• 5.13 OPKO Health Inc Company Overview
• 5.14 Shin Poong Pharm Co Ltd Company Overview
• 5.15 University of Kansas Company Overview

6 Viscosupplementation Devices - Recent Developments

• 6.1 Sep 09, 2019: Bioventus agrees to nationwide contract with UnitedHealthcare commercial plans
• 6.2 Sep 09, 2019: KalVista Pharmaceuticals reports fiscal first quarter results
• 6.3 Aug 22, 2019: Ampio Pharmaceuticals retains financial advisor and appoints Transaction Advisory Committee
• 6.4 Aug 12, 2019: Bioventus launches DUROLANE SJ (1mL) in Australia and New Zealand; receives expanded indications for DUROLANE (3mL)
• 6.5 Jul 31, 2019: Smith & Nephew second quarter and first half 2019 results
• 6.6 Jul 24, 2019: Anika reports second quarter 2019 financial results
• 6.7 Jul 17, 2019: OrthogenRx CEO awarded 2019 Entrepreneur of the Year
• 6.8 Jul 08, 2019: Anika appoints James Loerop as executive vice president of business development and strategic planning
• 6.9 May 21, 2019: New U.S. Patents granted for RegenLab
• 6.10 May 13, 2019: Anika to showcase regenerative medicine and orthobiologics portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine Congress
• 6.11 May 07, 2019: Smith & Nephew: Change of registered office
• 6.12 May 02, 2019: Smith & Nephew first quarter 2019 trading report
• 6.13 May 02, 2019: Anika reports first quarter 2019 financial results
• 6.14 Apr 30, 2019: Anika Therapeutics names Stephen Goldy as vice president of U.S. Sales
• 6.15 Apr 22, 2019: KalVista Pharmaceuticals names Daniel B. Soland to board of directors
• 6.16 Apr 03, 2019: Anika to highlight regenerative medicine and Orthobiologics Portfolio at 2019 Asia Pacific Orthopaedic Association Sports Meeting
• 6.17 Mar 29, 2019: PolarityTE announces Richard Hague, formerly from Sanofi, Genzyme and recently Anika Therapeutics as Chief Operating Officer
• 6.18 Mar 25, 2019: Smith & Nephew: Re-presented historical quarterly revenue analysis
• 6.19 Mar 22, 2019: Seikagaku launches HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Italy
• 6.20 Mar 18, 2019: Anika Therapeutics names Robert Richard as Vice President of research and development
• 6.21 Mar 14, 2019: Kalvista Pharmaceuticals reports fiscal third quarter result
• 6.22 Mar 06, 2019: Ampio updates regulatory status for Ampion
• 6.23 Feb 21, 2019: Anika reports fourth quarter and full year 2018 financial results
• 6.24 Feb 20, 2019: Smith & Nephew celebrates 18th year on FTSE4Good index
• 6.25 Feb 08, 2019: Smith & Nephew: Directorate changes
• 6.26 Feb 07, 2019: Smith & Nephew fourth quarter and full year 2018 results
• 6.27 Feb 06, 2019: Ampio updates status of pivotal clinical trial of Ampion to be carried out under a SPA
• 6.28 Feb 04, 2019: KYERON receives CE mark approval for
• 6.29 Feb 01, 2019: KalVista Pharmaceuticals names Brian J. G. Pereira as Board Director
• 6.30 Jan 29, 2019: Bioventus Launches DUROLANE in Malaysia and Selects Athrotech as Exclusive Distribution Partner
• 6.31 Dec 14, 2018: KalVista Pharmaceuticals reports fiscal 2018 second quarter results
• 6.32 Dec 13, 2018: Overland Park Surgical Suites first outpatient surgery center in region to offer robotics-assisted partial and total knee replacement surgery using the Navio surgical system
• 6.33 Dec 10, 2018: StimLabs announces Department of Veterans Affairs (VA) And Department of Defense (DoD) Agreements
• 6.34 Nov 01, 2018: Smith & Nephew third quarter 2018 trading report
• 6.35 Oct 25, 2018: Susan M. Stalnecker named to Bioventus Board of Managers
• 6.36 Oct 24, 2018: Anika Therapeutics announces Third Quarter 2018 Financial Results
• 6.37 Oct 24, 2018: Anika Therapeutics names Susan Vogt as Board Director
• 6.38 Oct 02, 2018: Bioventus Receives ANVISA Approval to Market DUROLANE in Brazil and Selects Pfizer as Exclusive Distribution Partner

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us